INSIGHTS ON CELL & GENE CLINICAL TRIALS

• High Efficiency T-Cell Editing

  Explore a modified synthetic sgRNA that allows you to achieve efficient, multigene knockout in primary human resting CD4+ T-Cells.

• Metastatic Breast Cancer - Global Clinical Trial Landscape (2023)

  Uncover why the collaboration between researchers, clinicians, regulatory bodies, and CROs remains crucial for innovative solutions and improved patient outcomes in the journey to address metastatic breast cancer challenges.

• Immune Checkpoint Inhibitors Global Clinical Trials Landscape (2023)

  Dive into the forefront of immune checkpoint inhibitors clinical trials with an exploration of the latest trends and key findings.

• 5 Stepping Stones To The Future State Of Rare Disease Clinical Development

  Review five essential steps that have the potential to propel rare disease clinical development into a new era of advancement and breakthroughs.

• Vor Bio Shares Progress For Patients with AML

  I talked to Dr. Robert Ang, President and Chief Executive Officer at Vor Bio about the company's VBP101 study for trem-cel in patients with acute myeloid leukemia (AML)

• Driving Down COGS: Leveraging Automation Technologies And Mitigating Risk

  The technologies aimed at automating and standardizing cell therapy production are poised to offer advanced therapy companies and CDMOs process-level improvements that streamline and accelerate workflows.

• The Eye: A Candidate For Modifier Gene Therapy

  Ocugen's Chairman, CEO and Co-founder, Shankar Musunuri ,Ph.D., MBA, provides an update on OCU400 and other ongoing trials, why the eye is a good target for gene therapy, the outlook for retinal gene therapy, and more.

• CGT Trials — The Synergy Of CRO And Specialty Logistics Collaboration

  Learn how the right CRO partner is crucial to support the uniquely complex logistical needs of CGTs while prioritizing the working conditions of investigators and the comfort of trial participants.

• 3 Steps For Cell & Gene Therapy Medical Affairs Teams To Provide Strategic Value

  Historically, medical affairs has been seen as more of a resource, as the group that answers complex scientific questions. However, medical affairs teams at cell and gene therapy companies must be more strategic.

• Opportunities To Accelerate Allogeneic Cell Therapy

  Learn more about the potential of allogeneic cell therapies to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.